The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Novacyt attaches great importance to the skills and experience of Yourgene's management and employees and recognises that the employees and management of Yourgene will be key to the success of the Enlarged Group. Tongue in cheek: Novacyt is looking forward to working with Yourgene's management and employees to support the future development of Yourgene within the Enlarged Group and to ensure that the business continues to thrive
I'm just hoping for a better bid if possible. Surely someone can beat that derisory offer.
And I’m also joining Andyken’s crusade
Why are holders selling 10% below the share price?
They must think it won’t happen or simply want to move on.
I’m holding and voting against in the hope we remain independent or a better bid emerges.
I notice they have accepted a scheme of arrangement that needs only 75% approval rather than 90% under a takeover. Shenanigans to the end. They must be worried it won’t pass.
How do we know Chang owns INEX by the way?
Hemo, don't sit on the fence!
I considered buying NCYT today until I read that useless, lying, amoral scumbag LR was being retained.
I mean it’s almost funny to think someone who has destroyed so much value in the target could keep their job in the bidder.
Caveat emptor NCYT shareholders, this guy is a moron.
So what potential suitors do we have for competing bids......
Illumina
Ambry
Labcorp
Thermo Scientific
Others??
More here https://yourgenehealth.com/wp-content/uploads/2023/07/Firm-Offer-Rule-2.7-Announcement.pdf
Following the Effective Date, it is intended that Lyn Rees, the current Chief Executive Officer of
Yourgene, and Dr John Brown, the current non-executive chairman of Yourgene, will remain on
the board of Yourgene and will join the board of Novacyt. Following the Effective Date, the
board of Novacyt will therefore comprise of two executive directors, being James McCarthy and
Lyn Rees, and five non-executive directors, being James Wakefield, Juliet Thompson, Andrew
Heath, Jean-Pierre Crinelli and Dr John Brown. Each other non-executive director on the
Yourgene Board will resign from the Yourgene Board with effect from the Effective Date. Dr Bill
20
Chang and Dr Joanne Mason will remain employed by Yourgene but will also resign from the
Yourgene Board with effect from the Effective Date
Https://twitter.com/Larry64450205/status/1675907112990285824/photo/1
Good lad Twix you know it makes sense.
Would be great if one if the really big outfits got interested. Hopefully would sack the lot of them and do it themselves.
Can't see why anyone is reluctant to try Andyken after this last shafting. Nothing to lose, let's see how far it goes.
Andrewkennedy079@gmail.com
Andrew Kennedy
Would be good to have you on board twix
Davand
what's AndyKens contact details please?
Directors have shafted everyone and bought cheap discounted shares and looking to sell out to line their pockets.
Sad really but it the way it’s been and truly how many LTH have made any money after today’s rise!
But this ain’t the only Aim company in this position so many will say 150% plus rise is better than nothing
Apologise and resign..ha ha ? he's laughing his bl oody head off at us all. Done everyone up like a kipper, bar himself.
Even gets to keep his job and even a seat on Ncyt s BOD FFS!
Andyken it is!! Won't affect anything as it's against him/them personally I believe.
In last 12 month, LR managed to destroy shareholders wealth by 97% by telling storying and asking people we are building business to deliver long term value to our LT shareholders.
Finally, today LR closed a deal at .522p which is still 90% below the what SP was 12 months ago. Many shareholders have been holding stocks for last 2-3 years and buying your bulls**t stories of long term value creation.
You will always be remembered as all-time wealth destroyer of long term shareholders. I'm surprised even after all this you haven't apologies to the shareholders and resigned!!
Last fundraise at a massive discount at 3p, BOD and mates bought hundreds of millions of shares, do nothing in the interim and then double their money selling the company. This stuff should be criminal.
Isn't the true figure £23M as they will pay off TF £6.5M too ?
I expect it will get voted through also, our hope is that another comes out of the woodworm to make a better offer.
GLT, so why haven't the others agreed like BGF ?
It will get voted through.
The recent circa 2.4b shares issued in Jan capital raising, 2.1b is with directors and institutions (BGF included). All these bought at 0.3p and now exiting at 0.522p or a good premium of over 70% in 6 months! Myers also averaged down and probably see this as the only way to realise YGEN value.
Then you have the proportion with original 727m holding including directors and BGF etc.
To get to 75%, it is circa 2.4b shares. Just the above pieces and a proportion of the original will get it there.
Then there will be retail investors, who like me, will vote for it.
I think, as bad as the price is, given current position - represents best chance to realise YGEN potential under another company with funds to accelerate growth + synergies in sales channels.
I will be accumulating Novacyt to continue the ride! GLA
If the choice is nothing or 0.0052p then I expect it will get voted through. Needs another offer to come in.